Cargando…

Role of Major Endocannabinoid-Binding Receptors during Mouse Oocyte Maturation

Endocannabinoids are key-players of female fertility and potential biomarkers of reproductive dysfunctions. Here, we investigated localization and expression of cannabinoid receptor type-1 and -2 (CB(1)R and CB(2)R), G-protein coupled receptor 55 (GPR55), and transient receptor potential vanilloid t...

Descripción completa

Detalles Bibliográficos
Autores principales: Cecconi, Sandra, Rossi, Gianna, Oddi, Sergio, Di Nisio, Valentina, Maccarrone, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627642/
https://www.ncbi.nlm.nih.gov/pubmed/31212770
http://dx.doi.org/10.3390/ijms20122866
Descripción
Sumario:Endocannabinoids are key-players of female fertility and potential biomarkers of reproductive dysfunctions. Here, we investigated localization and expression of cannabinoid receptor type-1 and -2 (CB(1)R and CB(2)R), G-protein coupled receptor 55 (GPR55), and transient receptor potential vanilloid type 1 channel (TRPV1) in mouse oocytes collected at different stages of in vivo meiotic maturation (germinal vesicle, GV; metaphase I, MI; metaphase II, MII) through qPCR, confocal imaging, and western blot. Despite the significant decrease in CB(1)R, CB(2)R, and GPR55 mRNAs occurring from GV to MII, CB(2)R and GPR55 protein contents increased during the same period. At GV, only CB(1)R was localized in oolemma, but it completely disappeared at MI. TRPV1 was always undetectable. When oocytes were in vitro matured with CB(1)R and CB(2)R but not GPR55 antagonists, a significant delay of GV breakdown occurred, sustained by elevated intraoocyte cAMP concentration. Although CBRs antagonists did not affect polar body I emission or chromosome alignment, GPR55 antagonist impaired in ~75% of oocytes the formation of normal-sized MI and MII spindles. These findings open a new avenue to interrogate oocyte pathophysiology and offer potentially new targets for the therapy of reproductive alterations.